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Abstract
Stabilized dynamic treatment regimes are sequential decision rules for individual patients
that not only adaptive throughout the disease progression but also remain consistent over
time in format. The estimation of stabilized dynamic treatment regimes becomes more com-
plicated when the clinical outcome of interest is a survival time subject to censoring. To
address this challenge, we propose two novel methods, censored shared-Q-learning and cen-
sored shared-O-learning. Both methods incorporate clinical preferences into a qualitative
rule, where the parameters indexing the decision rules are shared across different stages and
estimated simultaneously. We use extensive simulation studies to demonstrate the superior
performance of the proposed methods. The methods are further applied to the Framingham
Study to derive treatment rules for cardiovascular disease.
Key words: Dynamic treatment regimes, Shared decision rule, Stabilization, Statistical learn-
ing, Double robustness
1 Introduction
Dynamic treatment regimes (DTRs), also called adaptive treatment strategies (Murphy,
2003, 2005a), are sequential decision rules adapting over time to the time-varying charac-
teristics of patients. A DTR takes patient health histories as inputs and recommends the
next treatment strategy at each decision point. For example, treatment for lung cancer
usually involves regimens with multiple lines (Socinski and Stinchcombe, 2007). Clinicians
may update treatment for major depressive disorder according to factors emerging over time,
such as side-effect severity, treatment adherence, and so on (Murphy et al., 2007). In these
examples, the decision rules are different across different stages, yet in practice, it is not
unusual to have a common decision rule shared across different stages. For example, dia-
betes patients are recommended medication or lifestyle intervention when Hemoglobin A1c
(HbA1c) rises above a threshold, which is universal across the entire medication process.
Lung transplantation may be initiated for a cystic fibrosis patient if FEV1% (Forced Expira-
tory Volume in 1 second) value falls below 30%, which, again, remains the same throughout
the course of disease progression. Such shared decision rules are easier to implement in
practice throughout multiple decision points, in particular, when multivariate time-varying
covariates are potentially involved. We term them as stabilized dynamic treatment regimes
(SDTRs), which are also referred to as DTRs with shared parameters (Chakraborty et al.,
2016). We will use both terms interchangeably throughout the article.
Estimating an optimal DTR without shared parameters has been widely studied in the
past few years. A well-established approach is Q-learning (Watkins, 1989; Nahum-Shani
et al., 2012; Zhao et al., 2009; Laber et al., 2014; Goldberg and Kosorok, 2012), which
recursively estimates the conditional expectation of the outcomes given the current patient
history, assuming that optimal decisions are made in the future. The foregoing conditional
expectations are known as Q-functions. Semiparametric methods have also been proposed,
such as iterative minimization of regrets (Murphy, 2003) and G-estimation (Robins, 2004).
These methods are methodologically more complex, but could potentially provide efficiency
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gain. Recently, direct methods have become popular in the literature. They circumvent the
modeling of conditional means of the outcome given the treatment and covariates, and they
directly estimate the decision rule that maximizes the expected outcomes. Examples include
backward outcome weighted learning, simultaneous outcome weighted learning (Zhao et al.,
2015), and others (Robins et al., 2008; Orellana et al., 2010; Zhang et al., 2013). We refer
readers to Chakraborty and Moodie (2013) and Kosorok and Moodie (2015) for detailed
reviews of the current literature.
SDTRs are analogous to stationary Markov decision processes with function approxima-
tions (Sutton and Barto, 1998a). For solving Markovian decision problems, Antos et al.
(2008) proposed to minimize the squared Bellman error, where Bellman error quantifies
the difference between the estimated reward at any time point, and the actual reward re-
ceived. Chakraborty et al. (2016) proposed shared Q-learning to estimate the optimal shared-
parameter DTR when the decision rule at each stage is the same function of one or more
time-varying covariates. In particular, they formulated the decision rules as linear functions
of covariates, and the coefficients are assumed to be the same across stages. An alterna-
tive way of identifying an SDTR is the simultaneous G-estimation (Robins, 2004), which
can handle problems with shared parameters in principle, but its empirical performance is
largely unknown (Moodie and Richardson, 2010). The simultaneous outcome weighted learn-
ing approach proposed in Zhao et al. (2015) (with some modification) could be used when
the goal is to derive SDTRs. They converted the construction of DTRs into a simultaneous
nonparametric classification problem, where a multi-dimensional hinge loss of the expected
long-term outcome was employed. However, they did not explore modifying the method for
SDTRs.
Moreover, none of the aforementioned methods can handle censored survival outcome
when constructing an SDTR. In general, methods for accommodating time-to-event out-
comes are mostly limited to the regular DTR settings. This is mostly due to two main
challenges. First, the number of stages for each individual in the study is not fixed. This is
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because the event time can vary by individual, and the treatment is usually stopped once the
failure event happens. Second, the treatment/outcome status of a subject may be unknown
when censoring occurs. To this end, Goldberg and Kosorok (2012) developed a Q-learning
algorithm to adjust for censored data and allow a flexible number of stages. However, it
cannot be directly applied to solve for SDTRs.
In this paper, we propose two methods for solving SDTRs, termed as censored shared-
Q-learning and censored shared-O-learning (abbreviated from “outcome weighted learn-
ing”). The censored shared-Q-learning method generalizes the shared-Q-learning method
(Chakraborty et al., 2016) by applying the inverse probability of censoring weights to ac-
count for the uncertainty in the outcomes of censored subjects, where the censoring weights
need to be carefully constructed for each stage due to the multi-stage nature of the problem.
Similar to shared Q-learning, censored shared-Q-learning is an iterative procedure, which
identifies the optimal decision rule for each stage in a sequential/iterative manner. The
censored shared-O-learning method uses a non-iterative approach by directly maximizing
a concave relaxation of the inverse-probability-of-censoring weighted estimator of the ex-
pected survival benefit. To the best of our knowledge, this is the first article that provides
a thorough solution for deriving DTRs with shared parameters in the censored data setup.
The remainder of the paper is organized as follows. We introduce the general framework
of SDTR in Section 2. In Section 3, we introduce censored shared-Q-learning and censored
shared-O-learning along with the computation algorithms. We conduct numerical studies
that compare the proposed methods with Q-learning and shared Q-learning in Section 4.
Section 5 focuses on the application of the proposed methods to the Framingham Heart
data. Finally, we provide a discussion of open questions in Section 6.
3
2 Statistical framework
In this section, we present definitions and notations used in the paper, where we follow
Goldberg and Kosorok (2012) whenever possible. Throughout, we use uppercase letters to
denote random variables and lowercase letters to denote realizations of the random variables.
Let T be the maximal number of stages in a multistage study. Here, stages are re-
ferred to as clinical decision time points. A full trajectory of an observation sequence is
{X1, A1, Y1, . . . , XT , AT , YT}. For any decision point j = 1, . . . , T , the information of a pa-
tient is represented by (Xj, Aj, Yj), where X1 denotes the initial information, Xj denotes
the intermediate information collected between stages j − 1 and j when j > 0, and Aj is
the treatment assigned at the jth stage subsequent to observing Xj. We assume that there
are two possible treatments at each stage, i.e. Aj ∈ Aj = {−1, 1}. Yj is a non-negative
random variable that equals to either the length of the interval between decision time point
j and j + 1, or the length between decision time point j and failure time if the failure event
occurs in that stage. Yj can be viewed as the reward in the j
th stage, and
∑j
k=1 Yk is the
cumulative reward up to and including stage j. In our context, the sum
∑j
k=1 Yk is the total
survival time up to and including stage j. As the total survival times are broken down based
on the number of stages, this setup could introduce complexity to the trajectory structure.
In particular, if a failure event occurs before the final decision point T , the trajectory will
not be of full length (Goldberg and Kosorok, 2012). Subsequently, the number of stages for
different observations could be different. We denote the (random) total number of stages for
an individual by T¯ . Thus,
∑T¯
j=1 Yj is the overall survival time.
In this study, the observations are subject to censoring. Let C denote the censoring
time, taking values in the segment [0, τ ]. We assume that the censoring and failure times are
independent given the covariates of all previous stages. Let ∆j be the censoring indicator
at stage j, where ∆j = I(
∑j
k=1 Yk ≤ C). If no censoring event happens before the (j + 1)th
decision time point, then ∆j = 1 and the outcome Yj is observed. Hence, if a censoring event
occurs during stage T¯ , then C ≤ ∑T¯j=1 Yj, ∆T¯−1 = 1 and ∆T¯ = 0. In this case, we cannot
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observe the failure time that is censored by C. On the other hand, ∆T¯ = 1 if the failure time∑T¯
j=1 Yj is observed. While ∆j = 1 indicates that censoring has not occurred at stage j, it
does not necessarily mean
∑j
k=1 Yk is the time of event, which is different from the notation
of a typical survival analysis. Only ∆T¯ is the true failure time indicator.
We use an overbar to denote the collection of history information, e.g. the sequence of
treatments (A1, A2, ..., Aj) is represented by A¯j, and X¯j is the sequence of covariates up to
j. Let Hj = (X¯j, Y¯j−1, A¯j−1) ∈ Hj denote the accrued information at each stage, with the
convention that A0 = ∅, Y0 = 0 and H1 = X1 ∈ H1. A DTR is a sequence of deterministic
decision rules, d = (d1, . . . , dT ), where dj : Hj 7→ Aj is a function mapping from the space of
accrued information to the space of available treatments. Under d, a patient presenting with
Hj = hj at time j is recommended to treatment dj(hj). We use DT to denote the class of all
possible treatment regimes. Our goal is to identify the optimal dynamic treatment regime
d∗ ∈ DT , that maximizes the expected outcome if deployed to the whole population in the
future. Given that no information on survival is available beyond τ in the observed data,
the outcome of interest is truncated-by-τ expected survival. Let P d denote the distribution
of a trajectory given that Aj = dj(Hj), j = 1, . . . , T¯ . The optimal DTR is the sequence of
rules that maximizes
Ed
{
min
( T¯∑
j=1
Yj, τ
)}
, (1)
where Ed is the expectation with respect to P d. We refer to 1) as the value associated with
a regime d, denoted by V(d).
Following Goldberg and Kosorok (2012), we modify the trajectories when they are not of
full length or the overall survival time is greater than τ . The idea is to extend the information
to full length by introducing noninformative values at stages after the failure. If a failure
time occurs at stage j < T , we let X ′k = Xk for 1 ≤ k ≤ j + 1 and let the noninformative
X ′k = ∅, for j + 1 < k ≤ T . Similarly, we let A′k = Ak and Y ′k = Yk, for 1 ≤ k ≤ j. And
for j + 1 ≤ k ≤ T , we set Y ′k = 0 and draw A′k uniformly from A as the noninformative
values. If for some j,
∑j
k Yj ≥ τ , then we modify Y ′j to be Y ′j = max(τ −
∑j−1
k=1 Yj, 0), and
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modify the trajectory to be noninformative at all stages after j. For any DTR d ∈ DT , we
define a corresponding d′ for the modified trajectories, where the same action is chosen for
any triplet (x′j, a
′
j−1, y
′
j−1) if x
′
j 6= ∅, and a fixed action is chosen if x′j = ∅. It has been shown
in Goldberg and Kosorok (2012) that
Ed
′
( T∑
j=1
Y ′j
∣∣∣X1 = x1) = Ed{min( T¯∑
j=1
Yj, τ
)∣∣∣X1 = x1}. (2)
Subsequently, V(d) remains the same after this modification. In the following, we omit the
“prime” in the modified trajectories without the risk of ambiguity. Another complication
is due to censoring, where the trajectories themselves may be censored and cannot be fully
observed. This needs to be carefully handled when estimating SDTRs from the data.
3 Estimating DTRs with shared parameters for cen-
sored data
We often encounter time-varying covariates in longitudinal studies. To facilitate clinical im-
plementation, it could be beneficial to have a shared decision rule in its functional form across
multiple stages, while allowing the covariate values to change over time. In the following,
we propose two methods to estimate the DTRs with shared parameters using repeatedly
measured covariate information when the outcome is subject to censoring. The proposed
algorithms are based on Q-learning and O-learning in the multistage setup, respectively.
3.1 Censored shared-Q-learning
Due to delayed effects, we need to consider the entire treatment sequence in order to opti-
mize the long-term outcome. Results from the dynamic programming literature show that
d∗T (hT ) = arg maxaT QT (hT , aT ), where QT (hT , aT ) = E(YT |HT = hT , AT = aT ) and recur-
sively d∗j(hj) = arg maxaj Qj(hj, aj) whereQj(hj, aj) = E(Yj+maxaj+1 Qj+1(Hj+1, aj+1)|Hj =
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hj, Aj = aj) for j = T −1, . . . , 1 when the underlying generative distribution is known (Bell-
man, 1957; Sutton and Barto, 1998b). Q-learning is an approximate dynamic programming
algorithm that uses regression models to estimate the Q-functions Qj(hj, aj), j = 1, . . . , T
and then estimate d∗j(hj) recursively. Note that if a failure occurred prior to the j
th time
point, i.e., Xj = ∅, we set Qj as zero. A commonly used strategy is to estimate Q-functions
via linear regression using working models Qj(Hj, Aj; βj, ψj) = β
ᵀ
jHj0 + (ψ
ᵀ
jHj1)Aj, where
Hj0 and Hj1 (including intercepts) are possibly different features of Hj.
We focus on the setting where the decision rule parameters are shared across stages with
ψ1 = . . . = ψT = ψ, but βjs are left unshared. Let θj = (β
ᵀ
j , ψ)
ᵀ. Assuming the shared model
is correctly specified, the pseudo-outcome at the jth stage is Y˜j(θj+1) = Yj + β
ᵀ
j+1Hj+1,0 +
|ψᵀHj+1,1|, and Qj(Hj, Aj) = E{Y˜j(θj+1)|Hj, Aj}, j = 1, . . . , T − 1. Let Y˜T (θT+1) = YT . For
any stage j, we can write Qj(Hj, Aj) = β
ᵀ
jHj0 + (ψ
ᵀHj1)Aj. Hence, (β̂1, . . . , β̂T , ψ̂) can be
estimated (Chakraborty et al., 2016) via
argmin
β1,...,βT ,ψ
∑ᵀ
j=1
Pn
[
Y˜j(θj+1)− {βᵀjHj0 + (ψᵀHj1)Aj}
]2
, (3)
where Pn denotes the empirical averages of the data. However, Yj in the Y˜j(θj+1) may be
censored and unknown in the censoring data setup, and Y˜j(θj+1)s are defined by unknown
parameters.
Let SC(
∑j
k=1 Yk|Hj, Aj) = P (C >
∑j
k=1 Yk|Hj, Aj) be the conditional survival function
for the censoring time given history information up to stage j and treatment received at
that stage. In addition, we assume the conditional independent of censoring (i.e.
∑j
k=1 Yk ⊥
C|Hj, Aj). Then
E
{
∆j
SC
{
min(
∑j
k=1 Yk, C)|Hj, Aj
}∣∣∣Hj, Aj} = 1.
Let Uj = min(
∑j
k=1 Yk, C) −
∑j−1
k=1 Yk if the censoring occurs in the j
th stage, and Uj = Yj
otherwise. We further define U˜j(θj+1) = Uj + β
ᵀ
j+1Hj+1,0 + |ψᵀHj+1,1| for j ≤ T − 1 and
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U˜T (θT+1) = UT . Consequently,
E
[
Y˜j(θj+1)− {βᵀjHj0 + (ψᵀHj1)Aj}
]2
= E
([
U˜j(θj+1)− {βᵀjHj0 + (ψᵀHj1)Aj}
]2 ∆j
SC{min(
∑j
k=1 Yk, C)|Hj, Aj}
)
.
The quantity reflected in the above equation will only involve observed data, thus instead of
(3), (β̂ᵀ1 , . . . , β̂
ᵀ
T , ψ̂)
ᵀ can be estimated via a weighted least square procedure, with
argmin
β1,...,βT ,ψ
∑ᵀ
j=1
Pn
([
U˜j(θj+1)− {βᵀjHj0 + (ψᵀHj1)Aj}
]2 ∆j
ŜC{min(
∑j
k=1 Yk, C)|Hj, Aj}
)
, (4)
where ŜC is an estimator for SC .
We employ an iterative procedure for estimating θjs, which was also applied in Chakraborty
et al. (2016) for shared Q-learning without censoring. The censored shared-Q-learning algo-
rithm is presented below.
1. Estimate the conditional survival function for the censoring time ŜC{min(
∑j
k=1 Yk, C)|Hj, Aj}
at stage j, and construct the diagonal matrix
V =

VT 0 . . . 0
0 VT−1 . . . 0
...
...
...
0 0 . . . V1

where Vj = ∆j/ŜC{min(
∑j
k=1 Yk, C)|Hj, Aj}, j = 1, . . . , T .
2. Set the initial value of θ, denoted by θ̂(0) =
(
β̂
(0)ᵀ
T , . . . , β̂
(0)ᵀ
1 , ψ̂
(0)ᵀ
)ᵀ
.
3. At the (l + 1)th iteration, l = 0, 1, 2, . . .:
(a) Constructing the vector U˜(θ̂(l)) =
(
U˜T (θ̂
(l)
T+1)
ᵀ
, . . . , U˜1(θ̂
(l)
2 )
ᵀ)ᵀ
.
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(b) Solving for θ̂(l+1) = (ZᵀV Z)−1ZᵀV U˜(θ̂(l)), where
Z =

HᵀT0 0 . . . 0 H
ᵀ
T1AT
0 HᵀT−1,0 . . . 0 H
ᵀ
T−1,1AT−1
...
...
...
...
0 0 . . . Hᵀ10 H
ᵀ
11A1

.
4. Repeat steps (3a)-(3b) until ‖θ̂(l+1) − θ̂(l)‖ ≤  for a prespecified value  or until the
maximum number of iterations is reached.
A simple choice for the initial values of θ is to sets all parameters to zero, θ̂(0) =
(0ᵀ, . . . , 0ᵀ, 0ᵀ)ᵀ. In this paper, we let the initial values depend on the estimates from
censored Q-learning (Goldberg and Kosorok, 2012), where the parameters are not shared.
Denote the estimates as β̂
(0)
1 , . . . , β̂
(0)
T , ψ̂
(0)
1 , . . . , ψ̂
(0)
T . We combine the distinct estimates of
ψ̂
(0)
j into a single estimate via an average. The initial values of θ can be set as θ̂
(A) =(
β̂
(0)ᵀ
T , . . . , β̂
(0)ᵀ
1 , ψ̂
(A)ᵀ
)ᵀ
, where ψ̂(A) =
∑T
j=1 ψ̂
(0)
j /T .
3.2 Censored shared-O-learning
The censored shared-Q-learning algorithm requires correct specifications of Q-functions at
each stage. This could be unrealistic in the multistage setup since the underlying data
generating mechanism is usually complicated. In this section, we propose censored shared-
O-learning, which constructs the shared decision rules by directly targeting the overall benefit
of the decision rule.
Define pij(aj;hj) = P (Aj = aj|Hj = hj) for j = 1, . . . , T . We assume the following
conditions, including i) Aj is independent of all potential values of the outcome and future
variables conditional on Hj, j = 1, . . . , T ; and (ii) pij(1;Hj) is strictly between 0 and 1.
Assumption (i) is true in a sequential multiple assignment randomized trial (Murphy, 2005b)
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but unverifiable in an observational study. As shown in Zhao et al. (2015),
V(d) = Ed
(
T∑
j=1
Yj
)
= E
[
(
∑T
j=1 Yj)
∏T
j=1 I{Aj = dj(Hj)}∏T
j=1 pi(Aj;Hj)
]
, (5)
where I(·) is the indicator function. The right-hand side indicates V(d) equals the weighted
average of outcomes among those who received T treatments coinciding with that dictated
by d, with weights {∏Tj=1 pij(Aj;Hj)}−1. pijs are usually known in a sequential multiple
assignment randomized trial. If they are unknown, we can estimate pijs using methods such
as a logistic regression. Given the estimates pij(aj;hj), a plug-in estimator for V(d) based on
(5) is
V̂(d) = Pn
[
(
∑T
j=1 Yj)
∏T
j=1 I{Aj = dj(Hj)}∏T
j=1 pi(Aj;Hj)
]
.
However,
∑T
j=1 Yj may not be fully observed due to censoring. Following the notion in
Section 3.1, let UT = min(
∑T
j=1 Yj, C) and SC(
∑T
j=1 Yj|HT , AT ) = P (C >
∑T
j=1 Yj|HT , AT )
be the conditional survival function for the censoring time given history information up to
stage T . Denote the estimator of SC as ŜC . We can estimate V(d) in the scenario with
time-to-event outcomes using
V̂(d) = Pn
(
UT
∏T
j=1 I{Aj = dj(Hj)}∏T
j=1 pi(Aj;Hj)
· ∆T
ŜC(UT |HT , AT )
)
. (6)
The decision rules are formulated as fixed linear functions of the present variables at each
stage. Mathematically, they are presented as dj(Hj) = sgn(ψ
ᵀHj1), where Hj1 is a subset
of Hj important for determining the SDTRs similar to the one defined in Section 3.1. In
addition, we define sgn(0) = 1. Consequently, we maximize over ψ
V̂(ψ) = Pn
[
I{ min
j=1,...,T
Ajψ
ᵀHj1 ≥ 0} UT∆T∏T
j=1 pi(Aj;Hj)ŜC(UT |HT , AT )
]
.
where we use V̂(ψ) to denote V̂{sgn(ψᵀHj1)}, and substitute I{Aj = dj(Hj)} by I{AjψᵀHj1 ≥
10
0}.
It could be challenging to optimize V̂(ψ) directly due to the discontinuity of the indicator
functions. A computationally efficient approach is to replace the indicator by a concave
surrogate. This leads to an optimization problem of
max
(f1,...,fT )
Pn
(
φ
[
min
j=1,...,T
{AjψᵀHj1}
]
UT∆T∏T
j=1 pi(Aj;Hj)ŜC(UT |HT , AT )
)
, (7)
where φ is a concave function. In this paper, we will use φ(t) = − log(1 + e−t), which is
an analog of the logistic loss in the machine learning literature. However, other choices of
φ(t) are available; for example, analogs of exponential loss, hinge loss and others can also be
applied (Bartlett et al., 2006). The above objective function is not differentiable in ψ. To
account for the non-differentiability of the minimum function in (7), we instead consider a
soft-minimum function of u and v to replace min(u, v), which equals to − log{exp(−uK) +
exp(−vK)}/K, with K being a positive constant. Hence, the term minj=1,...,T {AjψᵀHj1},
in (7) can be replaced by its soft-minimum counterpart. We maximize
Φ(ψ) = Pn
(
UT∆T∏T
j=1 pi(Aj;Hj)ŜC(UT |HT , AT )
log
[
1 +K−1 ·
T∑
j=1
exp {−K(AjψᵀHj1)}
])
.
The derivative with respect to shared parameters of the decision rules ψ can be written as
∂Φ(ψ)
∂ψ
= Pn
(
UT∆T∏T
j=1 pi(Aj;Hj)ŜC(UT |HT , AT )
−∑Tj=1 exp {−K(AjψᵀHj1)} · (AjHj1)
1 +K−1 ·∑Tj=1 exp {−K(AjψᵀHj1)}
)
.
We can employ the orthant-wise limited-memory quasi-Newton algorithm proposed by An-
drew and Gao (2007). We also note that it is possible to write out the Hessian matrix for our
proposed objective function. However, we find it does not benefit the numerical performance
since the calculation of the second derivative is rather complicated and less efficient than a
numerical approximation using the Sherman–Morrison updating formula, as implemented in
the Broyden–Fletcher–Goldfarb–Shanno (BFGS) algorithm.
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Censored shared-O-learning maximizes the estimated mean outcome of a DTR over the
pre-specified class of DTRs with shared parameters. Hence, compared with censored shared-
Q-learning, it circumvents the need for estimating Q-functions at each stage. Furthermore,
it does not require modeling the censoring distribution at each stage but only needs to model
the censoring distribution at the final stage. However, censored shared-O-learning involves
an unknown parameter K, which controls the approximation of the soft minimum function
to the minimum function. In practice, we can use cross-validation to select the best K by
grid search over a prespecified set of candidate values.
Remark 1. In practice, interpretable and simple rules are preferable. Sparse penalty such
as LASSO can be applied in both censored shared-Q- and O-learning, where the coefficients
for unimportant variables will shrink to zero. For censored shared-Q-learning, we can solve
for θ̂(l+1) in step 3(b) using penalized weighted least squares. For censored shared-O-learning,
we can maximize the penalized objective
Φ(ψ)− τn‖ψ‖1,
where ‖ψ‖1 is the L1 norm of ψ and τn is a tuning parameter controlling the amount of
penalization. The orthant-wise limited-memory quasi-Newton algorithm, which is a limited-
memory BFGS algorithm that incorporates the `1 regulation, can still be applied in this case.
4 Simulation Studies
One of the motivations for the current work derives from the long-term care of patients
with diabetes. Patients are routinely examined for glycosylated hemoglobin (A1c) level ev-
ery three months, and treatments are recommended for tightly controlling A1c to prevent
adverse events such as hospitalization due to the disease. Our simulation mimics such a
setting, using the generative model similar to that of Timbie et al. (2010) and Ertefaie and
Strawderman (2018). We treat each check-up time as a decision point for determining treat-
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ment in the next three months. Our study consists of 10 decision points. The treatments
include metformin, sulfonylurea, glitazone, and insulin. Patients start with metformin and
augment with treatments sulfonylurea, glitazone, and insulin during the study period. At
each decision point, patients can either continue the current treatment or augment the treat-
ment. A binary discontinuation indicator is generated to represent patients’ intolerance to
treatment due to side effects, and patients who discontinue a treatment will take the next
available treatment. Nj is the number of augmented treatments by the end of interval j
where Nj ∈ {0, 1, 2, 3, 4}, and the number of augmented treatments N increases by one if
a treatment is augmented. The outcome of interest is time to hospitalization. Hence, each
patient’s trajectory continues until either a failure time occurs or the study ends. A censor-
ing variable is uniformly drawn from [0, 25]. When an event is censored, the trajectory ends
up to the time of censoring and the censoring times are given. Here are the steps we take to
generate the dataset:
• Baseline variables: Variables (BP0,weight0,A1c0) are generated from a multivariate
normal distribution with mean (12, 140, 7.7) and the covariance matrix diag(1, 1, 1),
where BP is the systolic blood pressure. Also, N0 = L0 = 0, where Lj is the discon-
tinuation indicator at stage j.
• Treatments: Given Nj, the sets of available treatments are ANj=0 = {0,metformin},
ANj=1 = {0, sulfonylurea}, ANj=2 = {0, glitazone}, ANj=3 = {0, insulin}, and ANj=4 =
{0}, where 0 means continue with the current treatment. The treatment is given as
follows,
– if A1cj < 7, continue with the current treatment and Nj = Nj−1.
– if A1cj > 8 and Nj−1 < 4, augment the current treatment and Nj = Nj−1 + 1.
– if 7 < A1cj < 8 and Nj−1 < 4, then a binary variable Zj is generated with
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probability
P (Zj = 1|A1cj−1, Nj−1, Lj−1) = exp(−0.2A1cj−1 + 0.5Nj−1 + 0.5Lj−1)
1 + exp(−0.2A1cj−1 + 0.5Nj−1 + 0.5Lj−1) ,
where Lj is the discontinuation indicator. If Zj = 1, the patient continues with
the current treatment, and we set Aj = −1, Nj = Nj−1. If Zj = 0, the treatment
is augmented, and we set Aj = 1, Nj = Nj−1 + 1.
• Treatment discontinuation indicator: A binary variable Lj is generated from a Bernoulli
distribution given the last augmented treatment. The treatment discontinuation rates
are P (Lj|Aj−1 = metformin) = P (Lj|Aj−1 = sulfonylurea) = P (Lj|Aj−1 = glitazone) =
0.20, and P (Lj|Aj−1 = insulin) = 0.35. We assume that P (Lj = 1|Aj−1 = 0) = 0.
• A1c, BP and weight at time j: we use the following generative model for A1c,
A1cj =
A1cj−1 − µj−1 + √
1 + σ2 + µj
,
where  ∼ N(0, 0.25), σ2 = 0.25 and
µj =
 µj−1(1− τAj) if A1cj−1 > 7, Nj−1 < 4, Aj 6= 0 and Lj 6= 1,µj−1 o.w. .
τAj is the treatment effect of Aj, where the treatment effects of metformin, sulfonylurea,
glitazone and insulin are 0.14, 0.20, 0.12, and 0.14, respectively. For the other time-
varying variables at time j: BPj = (BPj−1 + 1)/
√
1 + σ21 and weightj = (weightj−1 +
2)/
√
1 + σ22 , 1, 2 ∼ N(0, 0.25).
• Time to hospitalization: two generative mechanisms are considered. In Scenario 1, the
survival time at stage j, i.e., time to hospitalization, starting from the beginning of
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stage j, is generated by
log(Yj) = 2.5−0.5×|A1cj +0.5Nj−1−10|{I(A1cj > 0)−I(A1cj +0.5Nj−1 > 10)}2 +ε,
where ε follows a standard normal distribution. In Scenario 2, the survival time at
stage j is generated by
log(Yj) = 2.5− 0.5× |A1cj − 7|{I(A1cj > 0)− I(A1cj + 0.5Nj−1 > 10)}2 + ε.
The regret at each stage, i.e., the loss of reward incurred by not following the optimal
treatment regime at each stage, for Scenario 1 is 0.5 × |A1cj + 0.5Nj−1 − 10|{I(A1cj >
0) − I(A1cj + 0.5Nj−1 > 10)}2, and the regret for Scenario 2 is 0.5 × |A1cj − 7|{I(A1cj >
0) − I(A1cj + 0.5Nj−1 > 10)}2. Then the underlying optimal rule is the rule that yields
zero regret for all stages. Hence, in both scenarios, the optimal DTR is shared across stages,
and dj(Hj) = sgn(A1cj + 0.5Nj−1 > 10), where Hj = (A1cj,BPj,Weightj, Lj, Nj−1) in our
situation. In the first example, the difference between the treatment effects, also known as
the contrast function, can be specified as A1cj +0.5Nj−1−10. A linear model in censored Q-
learning or censored shared-Q-learning could be close enough to a correctly specified model.
However, this is not true in the second example, where a linear model is severely misspecified.
The proposed censored shared-Q-learning and censored shared-O-learning are compared
with censored Q-learning (Goldberg and Kosorok, 2012), which does not take into account the
shared data structure. We consider sample sizes of 2000 and 5000. We generate a validation
dataset with 50000 observations. The experiment is performed 500 times independently. In
each replicate, we calculate the mean response for all subjects in the validation dataset, had
the whole population followed the estimated rule. The averaged outcome is used to compare
different methods.
The censored shared-O-learning is implemented following (7) with φ(t) = − log(1 + e−t),
and K in the soft minimum function is set to 1. We looked at other values of K, which
15
gave similar results. The propensity scores at each stage are estimated using the treatment
proportion. For the censored shared-Q-learning, we use the linear model for the Q-function,
and parameters are estimated via weighted least squares as presented in (4). For the censored
Q-learning, the linear model is also used for the Q-function, where we let Qj(Hj, Aj) =
βᵀjHj0 + (ψ
ᵀ
jHj1)Aj. A weighted least square is utilized at each stage to solve for βˆj and ψˆj.
We use the Cox proportional hazards model to estimate SC{min(
∑j
k=1 Yk, C)|Hj, Aj} and
construct the weight at each stage. Note that in censored shared-O-learning method, only
SC{min(
∑T
k=1 Yk, C)|HT , AT} needs to be fitted. For all stages, we use A1c, BP and weight
at the baseline level to fit the Cox models. Let ZC denote the regressors, and λCi(t) denote
the hazard functions of censoring times for subject i. Then, λCi(t) = λC0(t) exp(β
ᵀ
CZCi),
where λC0(t) is the baseline hazard functions for censoring time. The estimator for βC , say
β̂C , maximizes the partial likelihood
n∏
i=1
{
exp(βᵀCZCi)∑
Uj≤Ui exp(β
ᵀ
CZCj)
}1−∆i
.
We use the Breslow estimator for the cumulative baseline hazard function ΛC0(t). An es-
timator of SC(t|Hji, Aji) for subject i is ŜC(t|HT¯ ,i, AT¯ ,i) = exp{−Λ̂C0(t)}exp(β̂
ᵀ
CZCi), where
Λ̂C0(t) is the estimator for ΛC0(t).
The means and the standard errors of the 500 values of the estimated DTRs on the val-
idation set for both scenarios are presented in Table 1. In Scenario 1, when the regression
model is close to being correctly specified, the censored shared-Q-learning leads to the best
performance. The censored Q-learning approach does not account for the shared data struc-
ture. Thus, there is a large variation in the obtained results. In Scenario 2, both censored
shared-Q-learning and censored Q-learning methods are sensitive to model misspecification.
Conversely, censored shared-O-learning has a robust performance, though it has slightly
worse results compared to censored shared-Q-learning method in Scenario 1. In practice,
it is unknown to us whether the regression model in censored shared-Q-learning could be
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correctly specified. We can use a cross-validation approach to choose the one that yields a
better result (e.g. larger estimated value) between censored shared-Q-learning and censored
shared-O-learning method.
5 Data Analysis
In this section, we apply the proposed methods to the Framingham Heart Study. The
Framingham Heart Study, established in 1948, is the first longitudinal prospective large-scale
cohort to study cardiovascular disease in the US. In the original cohort 5209 men and women
are monitored prospectively for epidemiological and genetic risk factors for cardiovascular
disease. There are maximum 32 examinations that occurred biannually during the 65 years
of followup (Tsao and Vasan, 2015). For illustration we consider only information from
the second to the sixth visits. In our dataset, 2236 subjects are available with complete
information on the risk factors at each measurement time and are free of cardiovascular
disease at the time of examination. The long-term outcome of interest is time to the onset of
the first major cardiovascular disease event or death, which has an event rate of 18.7% by the
end of the study. The median followup time is 25 years and the ages at baseline range from
17 to 70 with a median of 43. Traditionally, hypertension medication is recommended based
on the blood pressure level. However, the outcomes might be improved if other information
is also factored in. We utilize the Framingham Heart Study data to derive a decision rule
that informs a patient whether a hypertension medication should be taken at each decision
point, aiming to reduce the long-term risk of cardiovascular disease. Risk factors considered
in our prediction at each visit include age, diastolic blood pressure, cholesterol, high-density
lipoprotein, presence of diabetes, and smoking.
We first carry out a cross-validation procedure to select the method between censored
shared-Q-learning and censored shared-O-learning. At each run, we partition the whole
dataset into two parts, with one part serving as training data to estimate the SDTRs using
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both methods, and the other part as the validation set for implementing the estimated
SDTRs. When estimating SDTRs, the Kaplan–Meier method is used to fit the censoring
probabilities. The constructed SDTRs from the training set are evaluated using the empirical
value on the validation set adjusted for censoring. Each part served as the validation subset
once, and the cross-validated values are obtained by averaging the empirical values on both
validation subsets. The procedure is repeated 100 times.
Our implementation shows that both methods result in similar cross-validated values
of mean residual survival time in years (censored shared-Q-learning: 16.53, and censored
shared-O-learning: 16.80). Hence, we carry out both methods on the whole dataset. The
coefficients in the estimated SDTR are presented in Table 2, and Figure 1 shows the treat-
ment allocation rates from the constructed dynamic treatment regimes. The recommended
rules may look different between the two methods. This could happen when there are
patients who don’t have great differential treatment effects. In general, patients who are
currently on medication are more likely to continue taking it. There is a slight increase
in the proportion of subjects recommended for medication in the later years from censored
shared-Q-learning recommendations, compared with the current data. Conversely, fewer pa-
tients are recommended with medications using censored shared-O-learning rules. In either
case, the survival benefit could be significantly improved under the recommended SDTRs.
Figure 2 shows the Kaplan-Meier curves of time to first cardiovascular disease event for
patients whose treatments are consistent with censored shared-Q-learning recommendations
(left panel) and censored shared-O-learning recommendations (right panel) versus those who
are not, at the first and subsequent time points. It is clear that subjects whose medication
coincided with the recommendation had on average better survival outcome.
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6 Discussion
We proposed two new methods for constructing a SDTR with survival outcomes, which is
a fixed function of time-varying covariates over time. Such a rule yields an optimal treat-
ment strategy that can be easily implemented in practice. We provide efficient computing
algorithms to obtain the solution. Our method for the decision rule is based on a linear
combination of updated covariate information. It is also of interest to develop a more robust
tree structured decision rule, e.g. Zhu et al. (2017), without the assumption of linearity,
which has the additional advantage of ease of interpretation and dissemination. The cen-
sored shared-O-learning is proposed based on an inverse probability weighted estimator of
the expected outcome that would be achieved under a particular DTR. However, such an
estimator is potentially less efficient because it only uses outcome information from subjects
whose treatment assignments coincide with those dictated by the DTR of interest. In the
future, we can develop SDTRs via censored shared-O-learning using an augmented inverse
probability weighted estimator (Tsiatis, 2006; Zhang et al., 2013). Such an approach can
incorporate contributions from the subjects who did not receive the specified treatment as-
signments across all stages by estimating their pseudo outcomes using censored Q-learning.
Hence, it will improve efficiency over the censored shared-O-learning proposed here.
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Table 1: Mean values (s.e.) under the estimated optimal treatment rules; Opt: optimal value;
CQL: censored Q-learning; CSQL: censored shared-Q-learning; CSOL: censored shared-O-
learning.
Scenario n # of Stages Opt CQL CSQL CSOL
1 2000 10 9.71 7.56 (2.43) 9.63 (0.11) 8.25 (0.53)
1 2000 20 18.83 13.51 (5.83) 18.79 (0.07) 16.37 (1.62)
1 5000 10 9.71 7.75 (2.33) 9.66 (0.05) 8.19 (0.47)
1 5000 20 18.83 14.53 (5.42) 18.81 (0.03) 16.28 (1.70)
2 2000 10 9.68 5.89 (2.02) 4.96 (0.04) 7.86 (0.18)
2 2000 20 18.76 8.27 (4.26) 5.72 (0.09) 14.70 (0.21)
2 5000 10 9.68 5.38 (1.61) 4.96 (0.03) 7.86 (0.21)
2 5000 20 18.76 7.02 (3.49) 5.73 (0.05) 14.67 (0.71)
Table 2: Coefficients by CSQL and CSOL for the Framingham Heart Study (CSQL: censored
shared-Q-learning; CSOL: censored shared-O-learning)
CSQL CSOL
Intercept 1 -1
Age 0.020 0.005
Medication (Yes = 1) 0.414 0.269
Diastolic blood pressure -0.027 0.007
Total cholesteral -0.007 -0.000
HDL cholesterol 0.024 0.001
Diabetes (Yes = 1) -0.268 0.098
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Figure 1: Treatment allocation of the current data, recommended rules from CSQL and
CSOL; CSQL: censored shared-Q-learning; CSOL: censored shared-O-learning
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Figure 2: Kaplan–Meier Curves of Probability of Time to First cardiovascular disease Event
(left panel: CSQL; right panel: CSOL); CSQL: censored shared-Q-learning; CSOL: censored
shared-O-learning
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